Clinical Trial Update: Phase 2 Study of NX9 for Delineation of Bowel Anatomy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating NX9 for delineation of bowel anatomy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Carcinoma
• Gastrointestinal Disorders

Drugs mentioned

• NX9

Snippet

Sponsor: Nextrast, Inc. | Conditions: GI Carcinoma, GI Disorders | Phase 2 | Status: COMPLETED